NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Investors have until April 15, 2025, to ask the Court to b ...

NEW YORK, March 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/transmedics-gr ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of TransMedics Group, Inc. regarding a class action lawsuit alleging fraudulent practices and misleading statements by the company during the specified class period [1][2]. Group 1: Allegations Against TransMedics - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [1]. - It is claimed that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [1]. - The allegations suggest that these actions exposed TransMedics to increased scrutiny and regulatory risks, leading to materially false and misleading statements about its business and operations [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 28, 2023, to January 10, 2025 [1]. - Shareholders are encouraged to register for the class action by April 15, 2025, to potentially become lead plaintiffs [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices [3]. - The firm is dedicated to ensuring companies adhere to responsible business practices and good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock value [3].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for alleged misconduct during the Class Period from February 28, 2023, to January 10, 2025, with a lead plaintiff deadline set for April 15, 2025 [1][2]. Allegations Against TransMedics - The complaint alleges that TransMedics engaged in unethical practices, including the use of kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2]. - It is claimed that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight, which increased regulatory scrutiny and risk [2]. Lead Plaintiff Process - Investors in TransMedics have until April 15, 2025, to seek appointment as a lead plaintiff representative, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against TransMedics Group, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 15, 2025 [2][4]. Group 1: Allegations Against TransMedics - The complaint alleges that TransMedics and its executives made false and misleading statements, failing to disclose practices such as kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [4]. - It is claimed that TransMedics engaged in unsafe practices and concealed safety issues, leading to increased scrutiny and regulatory risks [4]. - The lawsuit asserts that the misleading statements about the company's business and operations resulted in investor damages when the true details became public [4]. Group 2: Market Reaction - Following the release of a report by Scorpion Capital on January 10, 2025, which described TransMedics as a significant healthcare fraud, the company's stock fell by 5.15% on that day [5][6]. - The stock experienced an additional decline of 6.9% on January 13, 2025, indicating a negative market reaction to the allegations [6]. Group 3: Legal Proceedings - Investors who purchased securities in TransMedics between February 23, 2023, and January 10, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][2]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to direct and oversee the litigation [7].

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=135488&from=4CLASS PERIOD: Febr ...

It's been a rough several months for TransMedics Group (TMDX -2.12%) shareholders. The stock has been beaten down by about 62% from the peak it set last August.The company's warm perfusion devices are the only ones approved by the Food and Drug Administration (FDA) to transport and store multiple solid organs. TransMedics is also the only solid organ transport device maker with a fleet of jets dedicated to transporting donated organs.Unfortunately, TransMedics isn't the only company selling FDA-approved war ...

Core Viewpoint - A lawsuit has been filed against TransMedics Group, Inc. and its senior executives for potential violations of federal securities laws, alleging misrepresentation and fraudulent practices [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Massachusetts, captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385 [2]. - Investors have until April 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - TransMedics is a commercial-stage medical technology company known for its "Organ Care System" (OCS), which maintains donor organs' viability before transplant [3]. Group 3: Allegations Against TransMedics - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, coercive tactics, and unsafe practices related to OCS, while also hiding safety issues and lacking oversight [4]. Group 4: Stock Performance and Impact - Following allegations of misconduct from U.S. Representative Paul Gosar, TransMedics' stock price fell approximately 4%, from $86.99 on February 21, 2024, to $83.14 on February 23, 2024 [5]. - After the resignation of the CFO and a narrowed financial outlook, a report from Scorpion Capital claimed that TransMedics' growth was driven by anti-competitive schemes and fraud, leading to a further 5% decline in stock price, from $72.55 on January 8, 2025, to $68.81 on January 10, 2025 [6].

SAN DIEGO, March 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), have until Tuesday, April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit. Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit charges TransMe ...

Core Viewpoint - A lawsuit has been filed against TransMedics Group, Inc. and certain senior executives for potential violations of federal securities laws, alleging misrepresentation and fraudulent practices [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Massachusetts, captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385 [2]. - Investors have until April 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - TransMedics is a commercial-stage medical technology company known for its "Organ Care System" (OCS), which maintains donor organs' viability before transplant [3]. Group 3: Allegations - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics, misrepresented safety practices, and lacked proper safety oversight [4]. - Specific accusations include overcharging for OCS and misappropriating corporate resources, leading to a stock price decline of approximately 4% from $86.99 to $83.14 between February 21 and February 23, 2024 [5]. Group 4: Stock Performance and Impact - Following the resignation of the CFO and a narrowed financial outlook in December 2024, a report by Scorpion Capital in January 2025 claimed that TransMedics' growth was driven by anti-competitive schemes and billing fraud, resulting in a further 5% decline in stock price from $72.55 to $68.81 between January 8 and January 10, 2025 [6].